Dabigatran etexilate
Total Payments
$5.5M
Transactions
640
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $5.5M | 640 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.5M | 640 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Secondary Prevention of Stroke | Boehringer Ingelheim Pharmaceuticals, Inc. | $2.5M | 0 |
| GLORIA AF Registry Phase II III Core | Boehringer Ingelheim Pharmaceuticals, Inc. | $1.8M | 1 |
| RE DUAL PCI | Boehringer Ingelheim Pharmaceuticals, Inc. | $536,213 | 0 |
| Prevention of secVT 0 to less than 18yrs | Boehringer Ingelheim Pharmaceuticals, Inc. | $244,841 | 0 |
| Phase IIb III efficacy and safety study | Boehringer Ingelheim Pharmaceuticals, Inc. | $236,488 | 0 |
| RE CIRCUIT Trial | Boehringer Ingelheim Pharmaceuticals, Inc. | $163,165 | 0 |
| Impact of Anticoagulation Therapy | Boehringer Ingelheim Pharmaceuticals, Inc. | $36,437 | 0 |
Top Doctors Receiving Payments for Dabigatran etexilate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Harrisonburg, VA | $5.5M | 639 |
| , M.D | Interventional Cardiology | Los Alamitos, CA | $6,128 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.5M
- Total Doctors 1
- Transactions 640
About Dabigatran etexilate
Dabigatran etexilate is a drug associated with $5.5M in payments to 1 healthcare providers, recorded across 640 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $5.5M was paid across 640 transactions to 1 doctors.
The most common payment nature for Dabigatran etexilate is "Unspecified" ($5.5M, 100.0% of total).
Dabigatran etexilate is associated with 7 research studies, including "Secondary Prevention of Stroke" ($2.5M).